Safety and PK-PD Study of Oral L-CIT in Preterm Infants With BPD±PH and NEC

A Phase I, Safety and Pharmacokinetics/Pharmacodynamics Study of Oral L-CIT Supplementation in Preterm Infants With BPD±PH and NEC

The purpose of this study is to evaluate the safety and explore the PK/PD of L-CIT supplementation in preterm infants to prevent the development of inflammatory pathways initiated by low levels of plasma CIT, specifically in preterm infants with post surgical NEC and BPD±PH.

Study Overview

• Status: Recruiting
• Conditions: Pulmonary Hypertension; NEC; BPD - Bronchopulmonary Dysplasia
• Intervention / Treatment: Dietary supplement: L-Citrulline

Detailed Description

Preterm infants are born with underdeveloped organs and immune systems, placing them at great risk for morbidity. They are more susceptible to inflammatory injury, particularly from conditions of prematurity mediated by inflammatory pathways such as bronchopulmonary dysplasia (BPD) and necrotizing enterocolitis (NEC).

L-CIT, an amino acid, is the first intermediate in the urea cycle as well as a precursor to arginine and nitric oxide (NO), which promotes blood flow. It is made in the intestine and has been shown to exert vasoprotective and anti-inflammatory effects. BPD-PH and NEC are two specific inflammatory diseases of prematurity involving CIT, arginine or NO deficiencies.

Evaluation of the safety and PK/PD of L-CIT supplementation for diseases involving CIT, arginine or NO deficiencies in preterm infants is important. Therefore, in this trial the investigator would like to evaluate the safety and pharmacokinetics/pharmacodynamics (PD) of L-CIT supplementation in preterm infants post surgical NEC and BPD-PH.

• Study Type: Interventional
• Enrollment (Estimated): 60
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Rachana Patel, MSc, CCRP; Phone Number: 202821 +1(416)-813-7654; Email: rachana.patel@sickkids.ca
• Study Contact Backup: Name: Rosanna Yankanah, MSc, CCRP; Phone Number: 202919 +1(416-)813-7654; Email: rosanna.yankanah@sickkids.ca

Study Locations

• Canada
  • Ontario
    • Toronto, Ontario, Canada, M5G 1X8
      • Recruiting
      • The Hospital for Sick Children
      • Contact: Principal investigator; Email: estelle.gauda@sickkids.ca

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 1 year to 10 months (Child)
• Accepts Healthy Volunteers: No

Description

Arm 1: BPD±PH:

Inclusion Criteria:

• Born ≤ 30 weeks at birth
• Post-menstrual age (PMA) ≥ 34 weeks
• Echocardiographic evidence of PH for infants with BPD+PH
• On invasive or non-invasive ventilation with RSS >2.0 for >12hours/day for at least 48 hours
• Informed written consent (parents/substitute decision maker)

Exclusion Criteria:

• Congenital Heart Disease [Exceptions: small atrial septal defect (ASD), small ventricular septal defect (VSD), small patent ductus arteriosus (PDA)]
• Infants with pulmonary vein stenosis
• Concurrent sepsis with hemodynamic instability
• Infants considered likely to die within next 7 days
• Any other condition that, in the opinion of the investigator, may adversely affect the infant's ability to complete the study or its measures or pose significant risk to the infant.

Arm 2: surgical NEC

Inclusion Criteria

• Born ≤ 30 weeks at birth
• Recovering from Stage IIIb NEC as per modified Bell's staging (pneumoperitoneum requiring surgery)
• Tolerating 30 ml/kg/day of enteral feeds
• On invasive or non-invasive ventilation (NIPPV/nCPAP) with RSS >2.0 for > 12hours/day for at least 48 hours, 10-14 days post surgery
• Informed written consent (parents/substitute decision maker)
• Considered medically stable by clinical team

Exclusion Criteria:

• Congenital heart disease (except small ASD, small VSD and non hsPDA)
• Pulmonary vein stenosis
• Concurrent sepsis with hemodynamic instability
• Likely to die within next 7 days
• Other condition significantly affecting pulmonary function independent of prematurity or NEC

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: BPD±PH; Arm 1: BPD±PH Total of 12-24 infants; 6-12 at each dose level of oral dosage form of L-Citrulline. (300 or 500 mg/kg/day divided q6 hours). Dose Level 1 = 300 mg/kg/day Dose Level 2 = 500 mg/kg/day	Dietary supplement: L-Citrulline; Citrulline is a nonessential amino acid made in the small intestine, occurs naturally in the body, and is believed to help reduce inflammation.L-CIT is a part of the urea cycle, produced as a by-product along with nitric oxide (NO).
Experimental: Surgical NEC; Arm 2: sNEC A total of 18-36 infants with Stage III NEC; 6-12 at each dose level of oral dosage form of L-Citrulline. (75, 150 or 225 mg/kg/day divided q6 hours) Dose Level 1 = 75 mg/kg/day Dose Level 2 = 150 mg/kg/day Dose Level 3 = 225 mg/kg/day	Dietary supplement: L-Citrulline; Citrulline is a nonessential amino acid made in the small intestine, occurs naturally in the body, and is believed to help reduce inflammation.L-CIT is a part of the urea cycle, produced as a by-product along with nitric oxide (NO).

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety of oral L-Citrulline administration	The number of patients with adverse events (AE) as a measure of safety and tolerability	5 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Association of blood pressure as one of the PD outcomes with maximum L-CIT concentration (Cmax)	Blood pressure of the study participants will be associated with PK measures of L-CIT exposure i.e. Cmax using univariate correlation approaches. The investigator will then attempt to construct a PK/PD model to link PK and PD measures found to be of significance during the univariate screen. Future larger studies will then be used to examine these relationships with adequately powered studies.	5 years
Association of stoma or nasogastric output as one of the PD outcomes with maximum L-CIT concentration (Cmax)	Stoma or nasogastric output of the study participants will be associated with PK measures of L-CIT exposure i.e. Cmax using univariate correlation approaches. The investigator will then attempt to construct a PK/PD model to link PK and PD measures found to be of significance during the univariate screen. Future larger studies will then be used to examine these relationships with adequately powered studies.	5 years
Association of stool output as one of the PD outcomes with maximum L-CIT concentration (Cmax)	Stool output from the study participants will be associated with PK measures of L-CIT exposure i.e. Cmax using univariate correlation approaches. The investigator will then attempt to construct a PK/PD model to link PK and PD measures found to be of significance during the univariate screen. Future larger studies will then be used to examine these relationships with adequately powered studies.	5 years
Association of blood pressure with the area under the concentration time curve (AUC) for L-CIT	Blood pressure of the study participants will be associated with PK measures of L-CIT exposure i.e. Area under Concentration time curve (AUC) using univariate correlation approaches. The investigator will then attempt to construct a PK/PD model to link PK and PD measures found to be of significance during the univariate screen.	5 years
Association of stoma or nasogastric output with the area under the concentration time curve (AUC) for L-CIT	Stoma or nasogastric output of the study participants will be associated with PK measures of L-CIT exposure i.e. Area under Concentration time curve (AUC) using univariate correlation approaches. The investigator will then attempt to construct a PK/PD model to link PK and PD measures found to be of significance during the univariate screen.	5 years
Association of stool output with the area under the concentration time curve (AUC) for L-CIT	Stool output from the study participants will be associated with PK measures of L-CIT exposure i.e. Area under Concentration time curve (AUC) using univariate correlation approaches. The investigator will then attempt to construct a PK/PD model to link PK and PD measures found to be of significance during the univariate screen.	5 years
Association of blood pressure with minimum L-CIT concentration (Cmin)	Blood pressure of study participants will be associated with PK measures of L-CIT exposure i.e. Cmin using univariate correlation approaches. The investigator will then attempt to construct a PK/PD model to link PK and PD measures found to be of significance during the univariate screen. Future larger studies will then be used to examine these relationships with adequately powered studies.	5 years
Association of stoma or nasogastric output with minimum L-CIT concentration (Cmin)	Stoma or nasogastric output from study participants will be associated with PK measures of L-CIT exposure i.e. Cmin using univariate correlation approaches. The investigator will then attempt to construct a PK/PD model to link PK and PD measures found to be of significance during the univariate screen. Future larger studies will then be used to examine these relationships with adequately powered studies.	5 years
Association of stool output with minimum L-CIT concentration (Cmin)	Stool output from study participants will be associated with PK measures of L-CIT exposure i.e. Cmin using univariate correlation approaches. The investigator will then attempt to construct a PK/PD model to link PK and PD measures found to be of significance during the univariate screen. Future larger studies will then be used to examine these relationships with adequately powered studies.	5 years
Correlation between CIT and arginine levels	Correlation between changes in CIT and arginine levels with nitrite/nitrate levels	5 years
Biomarkers of inflammation	The levels of IL-1β, IL-6, IL-8, IL-10, TNFα will be measured in tracheal aspirates and blood plasma. The aggregated levels fo these cytokines will reflect the inflammatory status of the study participant.	5 years
Oxidative stress	Oxidative stress (measured in tracheal aspirates and blood)	5 years
Respiratory Score (RSS)	The respiratory severity score (RSS) is a simplified severity score consisting of the mean airway pressure (MAP) multiplied by the fraction of inspired oxygen (FiO2). This score ranges from 0 to 12, with a higher score indicating more severe lung disease.	5 years
Desaturation index	The oxygen desaturation index (ODI) is commonly used to evaluate the severity of nocturnal hypoxemia. The ODI is defined as the number of episodes of oxygen desaturation per hour of sleep with desaturation events of >=10sec/ sampled hour.	5 years
Changes in Blood Pressure	Changes in diastolic and systolic blood pressure prior to and during CIT treatment.	5 years
Stoma, nasogastric or stool output	Volume of stoma, nasogastric or stool output prior to and during CIT treatment	5 years
Ventilation	Days on mechanical ventilation, non-invasive ventilation, and supplementary oxygen	5 years
BPD	number of days of survival free of BPD	5 years
Pre-discharge mortality	Number of study participants who died during NICU admission.	5 years
Postnatal steroid Use	Number of days study participants received postnatal steroids during their NICU stay.	5 years
Bayley's scale for infant development	Bayley Scales of Infant and Toddler Development is an extensive formal developmental assessment tool for diagnosing developmental delays in early childhood. BSID is the commonly used abbreviation for Bayley Scales of Infant and Toddler Development. Bayley-III includes a motor score, and fine and gross motor subtest scores. The standardized mean motor score is 100 (SD 15), with scores lower than 85 indicating mild impairment, and lower than 70 indicating moderate or severe impairment.In this particular trial, the investigator would be looking at the correlation between the inflammatory markers (IL-1β, IL-6, IL-8, IL-10, TNFα) and Neurodevelopmental outcomes from Bayley's scale during 18-24M follow up visit in babies received L-Citrulline during their NICU stay.	5 years
BPD severity	Moderate to severe BPD based on the different mode of ventilatory support needed at 36 wks PMA. No BPD = off all oxygen and positive pressure support Moderate BPD = low flow oxygen only Severe BPD= positive pressure support (high flow, CPAP, NIPPV, or ETT)	5 years

Collaborators and Investigators

• Sponsor: The Hospital for Sick Children
• Investigators: Principal Investigator: Estelle Gauda, MD, Division Head, Division of Neonatology

Study record dates

Study Major Dates

• Study Start (Actual): November 1, 2023
• Primary Completion (Estimated): December 1, 2027
• Study Completion (Estimated): March 1, 2028

Study Registration Dates

• First Submitted: October 26, 2022
• First Submitted That Met QC Criteria: November 23, 2022
• First Posted (Actual): December 5, 2022

Study Record Updates

• Last Update Posted (Estimated): December 1, 2023
• Last Update Submitted That Met QC Criteria: November 28, 2023
• Last Verified: November 1, 2023

More Information

Terms related to this study

• Keywords: L-Citrulline; BPD±PH; surgical NEC; Pharmacokinetic profile; Pharmacodynamic profile; Preterm neonates
• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Respiratory Tract Diseases; Lung Diseases; Infant, Newborn, Diseases; Lung Injury; Infant, Premature, Diseases; Hypertension; Ventilator-Induced Lung Injury; Hypertension, Pulmonary; Bronchopulmonary Dysplasia
• Other Study ID Numbers: 1000077413

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: Individual Participant Data will not be shared.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No